N‐Benzyl‐4‐((heteroaryl)methyl)benzamides: A New Class of Direct NADH‐Dependent 2‐trans Enoyl–Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity
Authors:
- 2 March 2016
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 11 (7) , 687-701
Abstract
Isoniazid (INH) remains one of the cornerstones of antitubercular chemotherapy for drug‐sensitive strains of M. tuberculosis bacteria. However, the increasing prevalence of multidrug‐resistant (MDR) and extensively drug‐resistant (XDR) strains containing mutations in the KatG enzyme, which is responsible for the activation of INH into its antitubercular form, have rendered this drug of little or no use in many cases of drug‐resistant tuberculosis. Presented herein is a novel family of antitubercular direct NADH‐dependent 2‐trans enoyl–acyl carrier protein reductase (InhA) inhibitors based on an N‐benzyl‐4‐((heteroaryl)methyl)benzamide template; unlike INH, these do not require prior activation by KatG. Given their direct InhA target engagement, these compounds should be able to circumvent KatG‐related resistance in the clinic. The lead molecules were shown to be potent inhibitors of InhA and showed activity against M. tuberculosis bacteria. This new family of inhibitors was found to be chemically tractable, as exemplified by the facile synthesis of analogues and the establishment of structure–activity relationships. Furthermore, a co‐crystal structure of the initial hit with the enzyme is disclosed, providing valuable information toward the design of new InhA inhibitors for the treatment of MDR/XDR tuberculosis.Keywords
Funding Information
- Global Alliance for TB Drug Development
This publication has 22 references indexed in Scilit:
- Bedaquiline: First FDA-approved tuberculosis drug in 40 yearsInternational Journal of Applied & Basic Medical Research, 2013
- Reducing safety-related drug attrition: the use of in vitro pharmacological profilingNature Reviews Drug Discovery, 2012
- Finding the sweet spot: the role of nature and nurture in medicinal chemistryNature Reviews Drug Discovery, 2012
- Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticityDrug Discovery Today, 2011
- Drug‐resistant tuberculosis: Past, present, futureRespirology, 2010
- Multidrug- and extensively drug-resistant tuberculosis: an emerging threatEuropean Respiratory Review, 2009
- Triclosan Derivatives: Towards Potent Inhibitors of Drug‐Sensitive and Drug‐Resistant Mycobacterium tuberculosisChemMedChem, 2009
- The influence of drug-like concepts on decision-making in medicinal chemistryNature Reviews Drug Discovery, 2007
- Multidrug-Resistant Mycobacterium tuberculosis: Molecular PerspectivesEmerging Infectious Diseases, 1998
- Modification of the NADH of the Isoniazid Target (InhA) from Mycobacterium tuberculosisScience, 1998